Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jul 05, 2023 10:15am
179 Views
Post# 35527186

RE:Pelareorep + Paclitaxel = Metastatic HR+/HER2– Breast Cancer

RE:Pelareorep + Paclitaxel = Metastatic HR+/HER2– Breast CancerDe-escalation of axillary surgery performed to remove breast cancer that has already spread to nearby lymph nodes and prevent further metastasis could reduce the likelihood of a patient with breast cancer developing postoperative complications, including arm lymphedema, chronic pain, chronic fluid collections, problems with range of motion in the shoulder, and axillary web syndrome.

https://www.onclive.com/view/dr-coopey-on-the-benefits-of-axillary-surgery-omission-or-de-escalation-in-breast-cancer

[The benefits seen with the de-escalation of axillary lymph node surgery for patients with breast cancer could further be enhanced with the early introduction of immunotherapy treatment strategies, like that with ONCY's pelareorep in combination with paclitaxel, for example, in contrast to conventional surgical intervention.]
<< Previous
Bullboard Posts
Next >>